About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker RDHL · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Jul 31, 2025Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
NCT04467840 · COVID-19, Lung Infection
Opaganib, Placebo
RDHL
RedHill Biopharma Limited
Phase 2/3Completed475Jul 18, 2021Registry ↗
Jul 23, 2025A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholang…
NCT03377179 · Cholangiocarcinoma, Cholangiocarcinoma Non-resectable
ABC294640, Hydroxychloroquine Sulfate 200 MG
RDHL
RedHill Biopharma Limited
Phase 2Completed65Jun 21, 2022Registry ↗
Mar 18, 2025RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
NCT04616924 · Pulmonary Mycobacterium Avium Complex Infection, Bronchiect…
RHB-204, Placebo
RDHL
RedHill Biopharma Limited
Phase 3Terminated12Aug 28, 2023Registry ↗
Mar 18, 2025Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
NCT03414489 · Cholangiocarcinoma, Cholangiocarcinoma Non-resectable
ABC294640
RDHL
RedHill Biopharma Limited
—No longer available——Registry ↗
Jun 6, 2024Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
NCT04723537 · Covid19
Part A: Upamostat 200 mg, Part A: Upamostat 400 mg
RDHL
RedHill Biopharma Limited
Phase 2/3Terminated61Dec 28, 2021Registry ↗
Jan 27, 2023Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Childr…
NCT04027894 · Traveler's Diarrhea
Rifamycin SV MMX, Placebo to Rifamycin SV-MMX
RDHL
RedHill Biopharma Limited
Phase 2Unknown142Jan 2025Registry ↗
Jan 27, 2023Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Childre…
NCT04026984 · Traveler's Diarrhea
Rifamycin SV-MMX, Placebo
RDHL
RedHill Biopharma Limited
Phase 2Unknown142Jun 2025Registry ↗
Mar 21, 2022A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
NCT04414618 · Coronavirus Infections
Opaganib, Placebo
RDHL
RedHill Biopharma Limited
Phase 2Completed42Nov 26, 2020Registry ↗
Jun 18, 2021ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma
NCT02757326 · Multiple Myeloma
Opaganib
RDHL
RedHill Biopharma Limited
Phase 1/2Terminated13May 2019Registry ↗
Feb 24, 2021Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in A…
NCT03009396 · Crohn Disease
RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 m…
RDHL
RedHill Biopharma Limited
Phase 3Completed54Nov 13, 2018Registry ↗
Dec 8, 2020Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
NCT01951326 · Crohn's Disease
RHB-104, Placebo
RDHL
RedHill Biopharma Limited
Phase 3Completed331May 2018Registry ↗
Aug 11, 2020Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen
NCT04502069 · COVID-19, Lung Infection
Opaganib
RDHL
RedHill Biopharma Limited
Phase 1/2Withdrawn0Feb 2021Registry ↗
Mar 16, 2020ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
NCT03198507 · Helicobacter Pylori Infection, Dyspepsia
RHB-105, Active Comparator
RDHL
RedHill Biopharma Limited
Phase 3Completed455Oct 24, 2018Registry ↗
Jan 7, 2020ABC294640 in Treating Patients With Advanced Solid Tumors
NCT01488513 · Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol…
sphingosine kinase-2 inhibitor ABC294640
RDHL
RedHill Biopharma Limited
Phase 1Completed22Aug 2014Registry ↗
Sep 24, 2019ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
NCT01980095 · Dyspepsia, Helicobacter Pylori Infection
RHB-105, Placebo
RDHL
RedHill Biopharma Limited
Phase 3Completed119Jun 2015Registry ↗
Feb 20, 2019BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteri…
NCT02246439 · Gastroenteritis, Gastritis
RHB-102, Placebo Oral Tablet
RDHL
RedHill Biopharma Limited
Phase 3Completed330Feb 13, 2017Registry ↗
Aug 28, 2018Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Re…
NCT02757105 · Irritable Bowel Syndrome With Diarrhea
BEKINDA, Placebo
RDHL
RedHill Biopharma Limited
Phase 2Completed127Jun 16, 2017Registry ↗
Dec 7, 2017Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymph…
NCT02229981 · Diffuse Large B Cell Lymphoma, Kaposi Sarcoma
ABC294640
RDHL
RedHill Biopharma Limited
Phase 1/2Withdrawn0Jun 2019Registry ↗
Jul 28, 2016Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Mu…
NCT01717664 · Relapsing Remitting Multiple Sclerosis
RHB-104
RDHL
RedHill Biopharma Limited
Phase 2Completed18Dec 2015Registry ↗

19 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:28 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances